Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma
To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.
Checked against the public recordLast updated Jun 11, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Alan Katz
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy * Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90) * surgical resection not feasible at time of initiation of pre-treatment workup -\> 6 months projected life span * ECOG 0-2 Exclusion Criteria: * previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Radiation Oncology, University of Rochester, Medical CenterRochester, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 11, 2020. Always confirm current availability with the study team.